Buckberry, Sam http://orcid.org/0000-0003-2388-6046
Liu, Xiaodong http://orcid.org/0000-0002-9315-3406
Poppe, Daniel http://orcid.org/0000-0002-6674-8420
Tan, Jia Ping
Sun, Guizhi
Chen, Joseph
Nguyen, Trung Viet
de Mendoza, Alex http://orcid.org/0000-0002-6441-6529
Pflueger, Jahnvi
Frazer, Thomas
Vargas-LandÃn, Dulce B. http://orcid.org/0000-0002-4773-9406
Paynter, Jacob M.
Smits, Nathan http://orcid.org/0000-0002-0156-5076
Liu, Ning
Ouyang, John F. http://orcid.org/0000-0002-1239-1577
Rossello, Fernando J.
Chy, Hun S.
Rackham, Owen J. L. http://orcid.org/0000-0002-4390-0872
Laslett, Andrew L.
Breen, James
Faulkner, Geoffrey J. http://orcid.org/0000-0001-5769-4494
Nefzger, Christian M. http://orcid.org/0000-0003-4631-5633
Polo, Jose M. http://orcid.org/0000-0002-2531-778X
Lister, Ryan http://orcid.org/0000-0001-6637-7239
Article History
Received: 4 June 2021
Accepted: 11 July 2023
First Online: 16 August 2023
Competing interests
: S.B., X.L., J. M. Polo and R.L. are co-inventors on a pending patent (PCT/AU2019/051296) filed by the University of Western Australia and Monash University related to this work. R.L. is a co-inventor on a patent (WO/2012/058634) concerning methods of characterizing the epigenetic signature of human induced pluripotent stem cells. Although unrelated to this manuscript, O.J.L.R. and J. M. Polo are co-inventors on a patent (WO/2017/106932) and are co-founders and shareholders of Mogrify, a cell therapy company. X.L. is a co-founder of iCamuno Biotherapeutics. The other authors declare no competing interests.